Skip to content

Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients

Effects of Exercise Training on Quadriceps Gene Expression in COPD-patients in Comparison to Alpha-1-Antitrypsin-deficiency-patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01380626
Enrollment
20
Registered
2011-06-27
Start date
2010-02-28
Completion date
2013-04-30
Last updated
2013-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alpha-1-antitrypsin-deficiency, Chronic Obstructive Pulmonary Disease

Keywords

alpha-1-antitrypsin-deficiency, COPD, exercise training, muscle biopsy

Brief summary

Chronic Obstructive Pulmonary Disease (COPD)-patients (caused by smoking-level) and Alpha-1-Antitrypsin-deficiency patients showed different developments during rehabilitation in regard to improvement of 6-minute-walking distance. The aim of this study is to investigate differences between training adaptations in COPD-patients and Alpha-1-deficiency patients. Both groups take part in a standardized multimodal 3-week-rehabilitation with strength and endurance training. In addition to conventional diagnostic procedures, muscle biopsies from the M. vastus lateralis will be conducted before and after rehabilitation program followed by biochemical, histochemical and immunohistochemical analysis of the probes.

Interventions

PROCEDUREexercise training

strength and endurance training, 5 time per week.

Sponsors

Grifols Therapeutics LLC
CollaboratorINDUSTRY
Alpha-1 Foundation
CollaboratorOTHER
Schön Klinik Berchtesgadener Land
Lead SponsorOTHER

Study design

Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* COPD * Alpha-1-Antitrypsine-deficiency, phenotype: ZZ * FEV1%pred. \<50

Exclusion criteria

* acute exacerbation * exacerbation in the last 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
aerobic and anaerobic enzymesday 2 and 23changes in quantity of enzymes from baseline to day 23

Secondary

MeasureTime frameDescription
maximal exercise capacity in incremental cycling testday 2 and 23Change in max. exercise capacity from baseline to day 23
6-minute-walking distanceday 3 and 24change in 6-minute-walking distance from baseline to day 24

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026